Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Возможность использования ривароксабана у пожилых пациентов с фибрилляцией предсердий - Справочник поликлинического врача №3 (2019)
Возможность использования ривароксабана у пожилых пациентов с фибрилляцией предсердий
А.Д. Эрлих. Возможность использования ривароксабана у пожилых пациентов с фибрилляцией предсердий. Справочник поликлинического врача. 2019; 3: 29-32.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Полный текст
Список литературы
1. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370–5.
2. Perera KS, Vanassche T, Bosch J et al. Global Survey of the Frequency of Atrial Fibrillation–Associated Stroke Embolic Stroke of Undetermined Source Global Registry. Stroke 2016; 47: 2197–202.
3. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. EHJ 2016; 37 (38): 2893–962.
4. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation. N Engl J Med 2002; 347: 1825–33.
5. Chao TF, Liu CJ, Lin YJ et al. Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study. Circulation 2018; 138 (1): 37–47.
6. Halperin JL, Hankey GJ, Wojdyla DM et al. ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014; 130 (2): 138–46.
7. Halvorsen S, Atar D, Yang H et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014; 35 (28): 1864–72.
8. Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363–72.
9. Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism. Systematic Review and Meta-Analysis Circulation 2015; 132: 194–204.
10. The State of Health and Aging in America 2004. Merck Institute of Aging and Health and Centers for Disease Control, 2004. https://www.cdc.gov/aging/pdf/State_of_Aging_and_Health_in_America_2004.pdf
11. Piccini JP, Hellkamp AS, Washam JB et al. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation 2016; 133: 352–60.
12. Steffel J, Verhamme P, Potpara TS et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. EP Europace 2018; 20 (8): 1231–42.
13. Coleman CI, Roberts MS, Sobieraj DM et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 2012; 28 (5): 669–80.
14. Andrade JG, Krahn AD, Skanes AC et al. Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. Can J Cardiol 2016; 32 (6): 747–53.
15. Phelan EA, Mahoney JE, Voit JC, Stevens JA. Assessment and management of fall risk in primary care settings. Med Clin North Am 2015; 99 (2): 281–93.
16. Inui TS, Parina R, Chang DC et al. Mortality after ground-level fall in the elderly patient taking oral anticoagulation for atrial fibrillation/flutter: a long-term analysis of risk versus benefit. J Trauma Acute Care Surg 2014; 76 (3): 642–9.
17. Yao X, Shah ND, Sangaralingham LR et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol 2017; 69 (23): 2779–90.
2. Perera KS, Vanassche T, Bosch J et al. Global Survey of the Frequency of Atrial Fibrillation–Associated Stroke Embolic Stroke of Undetermined Source Global Registry. Stroke 2016; 47: 2197–202.
3. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. EHJ 2016; 37 (38): 2893–962.
4. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation. N Engl J Med 2002; 347: 1825–33.
5. Chao TF, Liu CJ, Lin YJ et al. Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study. Circulation 2018; 138 (1): 37–47.
6. Halperin JL, Hankey GJ, Wojdyla DM et al. ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014; 130 (2): 138–46.
7. Halvorsen S, Atar D, Yang H et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014; 35 (28): 1864–72.
8. Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363–72.
9. Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism. Systematic Review and Meta-Analysis Circulation 2015; 132: 194–204.
10. The State of Health and Aging in America 2004. Merck Institute of Aging and Health and Centers for Disease Control, 2004. https://www.cdc.gov/aging/pdf/State_of_Aging_and_Health_in_America_2004.pdf
11. Piccini JP, Hellkamp AS, Washam JB et al. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation 2016; 133: 352–60.
12. Steffel J, Verhamme P, Potpara TS et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. EP Europace 2018; 20 (8): 1231–42.
13. Coleman CI, Roberts MS, Sobieraj DM et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 2012; 28 (5): 669–80.
14. Andrade JG, Krahn AD, Skanes AC et al. Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. Can J Cardiol 2016; 32 (6): 747–53.
15. Phelan EA, Mahoney JE, Voit JC, Stevens JA. Assessment and management of fall risk in primary care settings. Med Clin North Am 2015; 99 (2): 281–93.
16. Inui TS, Parina R, Chang DC et al. Mortality after ground-level fall in the elderly patient taking oral anticoagulation for atrial fibrillation/flutter: a long-term analysis of risk versus benefit. J Trauma Acute Care Surg 2014; 76 (3): 642–9.
17. Yao X, Shah ND, Sangaralingham LR et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol 2017; 69 (23): 2779–90.
Авторы
А.Д. Эрлих
ГБУЗ «Городская клиническая больница №29 им. Н.Э. Баумана» Департамента здравоохранения г. Москвы, Москва, Россия
ГБУЗ «Городская клиническая больница №29 им. Н.Э. Баумана» Департамента здравоохранения г. Москвы, Москва, Россия
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.